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Aims: The risk of gestational diabetes mellitus (GDM) is increased in overweight and obese women 
potentially involving secreted mediators from adipose tissue. Our main aim was to evaluate if 
circulating adipokines and monocyte/macrophage markers were dysregulated in GDM and the 
influence body mass and indices of glucose metabolism had on this association. We further explored if 
early detection of these markers improved prediction of GDM and if they remained modified during 
long-term follow-up. 
Materials and Methods: Population-based prospective cohort study in 273 pregnant women with 
markers measured four times during pregnancy and at 5 years follow-up.  
Results: sCD163 was higher (25% at 14-16 weeks, p<0.001) and adiponectin lower (-17% at 14-16 
weeks, p<0.01) early in pregnancy and at 5 years follow-up in GDM women, independent of BMI and 
other GDM risk factors. Leptin, adiponectin and chemerin were robustly associated with glucose 
metabolism throughout pregnancy while sCD163 was inversely associated with β-cell function early in 
pregnancy in women with increased BMI. Finally, the markers at 14-16 weeks displayed modest 
discriminatory properties with regard to prediction of GDM (AUC<0.7). Using a combination of 
fasting glucose and sCD163, 53% of GDM could be identified when 25% of the population scored 
positive suggesting some merit in a multimarker approach. 
Conclusions: sCD163 and adiponectin were dysregulated in GDM, independent of body mass. None 
of the adipokines or monocyte/macrophage activation markers displayed clinically useful properties 
alone for early detection of GDM. Activation of monocytes/macrophages may be an important event 
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Gestational diabetes mellitus (GDM), defined as glucose intolerance with onset or first recognition 
during pregnancy, affects 4-18 % of pregnant women 
1
. The risk of GDM is increased in overweight 
and obese women potentially involving secreted mediators from adipose tissue 
2
. Thus, crosstalk 
between adipose tissue and other insulin targets tissues are mediated by a number of molecules 
secreted from adipocytes which may contribute to regulation of maternal energy metabolism and 
insulin resistance 
3-6
. Several studies have demonstrated associations between circulating levels of 
adipokines early in pregnancy and risk for GDM, also after controlling for body mass index (BMI) 
7, 8
, 
indicating that the metabolic activity and/or distribution of adipose tissue may link adipokines to the 
development of GDM.  
In addition to a central role for adipokines generated by adipocytes and cells of the stromal 
vascular function in linking obesity, low-grade inflammation and insulin resistance, infiltration of 
“classical” inflammatory cells into adipose tissue may also be central 
9-11
. The predominant leukocyte-
derived cells in adipose tissue are macrophages which have overlapping functions with adipocytes, 
and positively correlate with adipocyte size, BMI, and expression of pro-inflammatory cytokines 
12
. 
While numerous studies have evaluated adipokine levels in GDM, few have systematically 
evaluated the temporal course of multiple adipokines and/or relevant markers of 
monocyte/macrophage activation in relation to the development of GDM. The STORK study was a 
prospective cohort study following 1031 Norwegian healthy pregnant women 
13
. Participants were 
invited to participate in a follow-up 5 years after pregnancy to evaluate indices of glucose metabolism 
and cardiovascular risk. 300 women participated in the follow-up and we have previously evaluated 
glucose metabolism
14
, body composition 
15
, CV risk 
16
 and a range of inflammatory biomarkers 
17-19
 in 
this cohort. Using this cohort, we measured maternal serum levels of some adipokines (adipsin, 
adiponectin, chemerin, interleukin 1 receptor antagonist (IL1Ra), at least partly regarded as an 
adipokine 
20
, leptin, resistin, clusterin) and the monocyte/macrophage activation markers soluble (s) 
CD163 and sCD14 four times during pregnancy and at 5 years follow-up in 273 women (i.e. excluding 
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women with preeclampsia and hypertension without GDM) and evaluated the association with the 
development of GDM diagnosed with the IADPSG 2010 criteria. Specifically, we aimed to evaluate i) 
if the temporal profile of these markers was different in uncomplicated pregnancy vs. GDM ii) if 
dysregulated levels of these markers was explained by differences in BMI iii) associations with 
different indices of glucose metabolism iv) if levels of these markers early in pregnancy could predict 
the development of GDM and finally, v) if dysregulated levels of these markers was sustained during 
long-term follow-up.  
Materials and Methods 
The STORK study, a prospective longitudinal cohort study in which 1031 low-risk women of 
Scandinavian heritage were followed throughout their pregnancy and gave birth at Oslo University 
Hospital Rikshospitalet between 2002 and 2008 
13
. Each pregnant woman had four study-related 
antenatal visits at weeks 14-16, 22-24, 30-32, and 36-38. BMI was calculated at each visit. A 75g 
OGTT was performed on all women at 14-16 and 30-32 weeks of gestation. A follow-up OGTT was 
performed 5-years postpartum in 300 women
15
. We included only the women that had participated 
both during pregnancy and follow-up in this particular study. Women with preeclampsia, preterm birth 
and hypertension without GDM were excluded, and this study ended up with 273 participants (Figure 
1). Written informed consent was obtained from all study participants. All clinical investigations were 
conducted in accordance with the principles enshrined in the Declaration of Helsinki. The study was 
approved by the Regional Committee for Medical Research Ethics of Southern Norway in Oslo, 
Norway. 
Measurements of glucose and insulin from OGTT 
All 75g OGTTs were performed in the morning after an overnight fast and glucose levels measured as 
previously reported 
15
. Briefly, glucose was measured in serum samples collected at antenatal visits at 
14 -16 and 30–32 weeks and frozen until analysis, using the hexokinase method at an accredited 
clinical chemistry laboratory at Oslo University Hospital (Cobas 6000 from Roche). For the 5-year 
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follow-up visit, fasting glucose measurements were collected using an Accu-check Sensor glucometer. 
Insulin levels were assayed in duplicate (RIA, DPC, Los Angeles, CA, USA) as previously reported 
15
. 
Diagnosis of GDM and pre-diabetes 
GDM was diagnosed using the IADPSG 2010 criteria (fasting plasma glucose (FPG) 5.1–6.9 mmol/L, 
1h plasma glucose ≥10.0 mmol/L or 2h plasma glucose 8.5–11.0 mmol/L) following a 75 g oral 
glucose load at gestational week 30-32. Pre-diabetes was diagnosed at the 5-year follow-up visit using 
the following criteria: FPG 5.6–6.9 mmol/L or 2h plasma glucose 7.8–11.0 mmol/L after 75 g OGTT 
21
. 
As previously reported 6.7 % of the women at 5 years were found to be pre-diabetic
15
.  Of these 18.4 
% were previously diagnosed with GDM and 4.5 % with non-GDM. 
Insulin sensitivity was measured with the Matsuda index 10 000/√ of (fasting glucose 
(mmol/L)×fasting insulin (mU/L)×(mean glucose (mmol/L)×mean insulin (mU/L)) during 75g OGTT. 
This index is a measure of whole body insulin sensitivity that has been validated against the 
euglycemic-hyperinsulinemic clamp 
22
. β-cell function was assessed with the insulin secretion-
sensitivity index (ISSI-2) (area under the curve insulin(mU/L)0−120 /glucose(mmol/L)0−120 ×Matsuda), 
validated against the disposition index from the intravenous glucose tolerance test 
23
. HOMA-IR was 
calculated as fasting insulin (mU/L)×fasting glucose (mmol/L)/22.5, as described by Matthews et al. 
24
.  
Blood sampling and measurement of adipokines and macrophage markers 
Peripheral venous blood was drawn into pyrogen-free tubes with EDTA as anticoagulant. The tubes 
were immediately immersed in melting ice and centrifuged within 30 minutes at 2,000g for 20 minutes 
to obtain platelet-poor plasma. All samples were stored at -80°C and thawed <3 times. Adipokines 
(adipsin (DY1824), adiponectin (DY1065), chemerin (DY2324), leptin (DY398), resistin (DY1359), 
clusterin (DY5874)) and monocyte/macrophage markers (sCD163 (DY1607), sCD14 (DY383)) were 
measured in duplicate using commercially available antibodies (R&D Systems, Minneapolis, MN, 
USA) while CRP (DY1707) was measured as previously reported
19
, also with commercially available 
antibodies (R&D Systems, Minneapolis, MN, USA), and IL-1Ra (900K574) was measured with 
7 
 
antibodies from PeproTech (Rocky Hill, NJ, USA), in a 384 format using the combination of a 
SELMA (Jena, Germany) pipetting robot and a BioTek (Winooski, VT, USA) dispenser/washer 
(EL406). Absorption was read at 450 nm with wavelength correction set to 540 nm using an ELISA 
plate reader (Synergy H1 Hybrid, Biotek, Vinooski, VT, USA). Leptin and adiponectin analysis has 
been published before 
17
. Intra- and inter-assay coefficients of variation were <10% for all assays. 
Statistical analysis 




 percentile) when 
skewed. Comparison between women with GDM and non-GDM were performed using t-test or 
Mann–Whitney's U depending on distribution, and χ
2
 test for categorical variables. Temporal changes 
in markers were assessed with repeated measures ANOVA and if  the group effect was significant, 
multivariate linear regression analyses were carried out on log transformed variables (if skewed) at 
each visit adjusting first with BMI and then age, CRP, diabetes in family and parity. Associations 
between protein levels and indices of glucose metabolism were assessed using multivariate regression 
including BMI as a covariate. If an interaction between protein level and BMI was detected, the 
association was explored and the interaction term reported, otherwise univariate associations are 
reported.  
Prediction of GDM by marker level at 14-16 weeks was evaluated by receiver operating 
characteristic (ROC) analysis. Logistic regression identified the strongest predictors of GDM. BMI, 
age, CRP, diabetes in family, parity and fasting glucose were forced in step 1 and the protein 
biomarkers were included by backward stepwise addition in step 2. Accuracy was represented using 
the terms sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) 
as described previously
14
. P-values are two-sided and p<0.05 was considered statistically significant. 
Results 
Table 1 shows the characteristics of the study population at 14-16 weeks, 30-32 weeks of pregnancy 
and at the time of the 5-year follow-up visit, respectively, stratified into those women who did and did 
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not have GDM in the index pregnancy using IADPSG 2010 diagnostic criteria 
25
. In general, women 
who developed GDM were older and had higher BMI, CRP and glucose measures.  
Maternal adipokine and monocyte/macrophage marker profiles during pregnancy (Figure 2) 
Circulating chemerin, IL-1Ra, leptin, resistin, sCD14 and sCD163 levels increased while clusterin and 
adiponectin decreased during pregnancy (p<0.001). Levels of adipsin decreased initially with a 
subsequent increase, giving levels similar at 14-16 and 36-38 weeks. An interaction between the 
temporal course (i.e. time) and GDM group was observed for sCD163 (p=0.073), leptin (p<0.001) and 
resistin (p=0.023). The difference between GDM and non-GDM as a whole group were significant for 
sCD163 (p=0.002), IL1Ra (p=0.042), leptin (p=0.031) and adiponectin (p=0.001) (Figure 2).  
We next investigated markers that were different with regard to GDM status at individual 
time-points. In general, all markers correlated more strongly with BMI compared to weight gain and 
BMI was used for adjustment purposes. After adjusting for BMI at each visit, sCD163 remained 
elevated and adiponectin lower at visit 14-16 and 22-24 weeks, and these differences persisted 
following further adjustment for age, CRP (to adjust for general systemic inflammation), diabetes in 
family and parity. The association between IL-1Ra and leptin and GDM was markedly attenuated and 
not significant following adjustment for BMI.  
Maternal adipokines and monocyte/macrophage activation markers and associations with BMI, CRP 
and glucose measures during pregnancy 
As seen in Figure 3, sCD163, IL1Ra, leptin, adiponectin and chemerin was associated with BMI at 
both 14-16 and 30-32 weeks. Adipsin was associated with BMI only at 14-16 weeks. Further, IL1Ra, 
leptin, and chemerin correlated positively with CRP at 14-16 and 30-32 weeks. sCD163 was positively 
correlated with CRP at 14-16 weeks and adiponectin was inversely associated with CRP at 30-32 
weeks.  
We next investigated which of the markers that was associated with glucose measures, in 
univariate and multivariate analysis adjusted for BMI (Figure 3). At 14-16 weeks of gestation, sCD163 
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was modestly inversely associated with insulin sensitivity. For β-cell function (ISSI-2) at 14-16 weeks, 
an interaction between BMI and sCD163 was observed (Figure 3A) indicating an inverse association 
between sCD163 and β-cell function only in individuals with high BMI. Further, sCD163 was 
inversely associated with insulin sensitivity and positively with insulin resistance at 30-32 weeks, also 
following adjustment for BMI. IL-1Ra was inversely associated with β-cell function in BMI adjusted 
analysis at both time-points. Leptin and chemerin was inversely correlated with insulin sensitivity and 
positively associated with insulin resistance, and although attenuated, remained significantly 
associated after adjusting for BMI. An opposite pattern was observed for adiponectin, which also 
correlated positively with β-cell function at both time-points.  
Adipokines and monocyte/macrophage markers at 14-16 weeks for prediction of GDM  
We next assessed the discriminatory properties of the adipokines from the 14-16 week OGTT to 
predict GDM at 30-32 weeks using ROC analysis. As shown in Figure 4A, the accuracy varied but 
was in general poor or modest for all markers (i.e., AUC 0.5-0.7). The best performance was achieved 
for IL-1Ra and sCD163. Multivariable regression (Figure 4B) revealed the low levels of adiponectin 
(34% reduced risk per SD increase in log adiponectin) and high levels of IL-1RA (57% increased risk 
per SD change in log IL-1Ra) and sCD163 (103% increased risk per SD change in log sCD163) were 
associated with GDM in adjusted analysis. Diagnostic test characteristics were further analyzed for 
sCD163 (Figure 4C). Sensitivity was poor at higher percentiles of sCD163 and only approximated 
80% at around the 50 percentile (i.e. half of the population is characterized as positive). Specificity 
rapidly declined and was 78% at the 25
th
 percentile and 58% at the 50
th
 percentile. Figure 4D shows 
the sensitivity of fasting glucose, sCD163 and their combination across different percentiles and shows 
that a more sensitive prediction of GDM is achieved when combing these to. Thus, when 25% of the 
population display increased glucose and sCD163, 53% of GDM cases can be identified.  
Adipokines 5 years after pregnancy 
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After 5 years post-partum adiponectin, leptin, sCD163, chemerin, IL1Ra were different between 
previous GDM and non-GDM. When adjusting for BMI, age, CRP, diabetes in family and parity we 
found adiponectin, adipsin and sCD163 still different between the groups (Table 2). 
Discussion 
Our prospective cohort study evaluating a range of circulating adipokines and monocyte/macrophage 
activation markers during normal and GDM pregnancies revealed i) sCD163 was higher and 
adiponectin lower early in pregnancy and at 5 years follow-up in GDM women, independent of BMI 
and other GDM risk factors. ii) leptin, adiponectin and chemerin were robustly associated with indices 
of glucose metabolism throughout pregnancy while sCD163 was inversely associated with β-cell 
function early in pregnancy in women with increased BMI. iii) sCD163 at 14-16 weeks in combination 
with glucose levels enhanced prediction of GDM. Further evaluation of sCD163 as a risk marker and 
interactions between BMI, macrophage activation and β-cell function early in pregnancy of GDM 
women is warranted.   
In our study, weight gain was less pronounced in GDM pregnancies, and the difference in 
BMI compared to non-GDM women was smaller approaching term. Thus, the largest difference in 
markers between these groups was observed early in pregnancy. In particular adiponectin was low and 
sCD163 elevated in GDM, and although this association was attenuated in BMI adjusted analysis, it 
persisted indicating both BMI dependent and independent associations with GDM for these proteins. 
Thus, adiponectin remained associated with integrated measures of glucose metabolism both early and 
late in pregnancy supporting its prominent role in glucose regulation 
26, 27
. As GDM women are at 
increased risk of developing T2DM, our finding that both adiponectin and sCD163 were dysregulated 
at 5-years follow-up, supports these proteins as risk factors for T2DM 
27, 28
. 
Soluble CD163 has been identified as a macrophage specific risk predictor for developing 
T2DM 
28
 and marker of obesity-related insulin resistance 
29, 30
. Our data support a previous smaller 
study showing increased sCD163 in 18 GDM women compared to 20 BMI matched controls at 39-40 
weeks of gestation 
31
. The increased sCD163 in late pregnancy, as opposed to early changes in our 
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study, could be related to a higher macrophage infiltration in obese subjects. Indeed, adipose tissue 
explants from these women produced more sCD163 compared to their BMI matched controls 
31
. In 
addition, they detected increased staining of CD163 in placental tissue, presumably from placental 
macrophages as well as increased secretion from placental explants suggesting the placenta as an 
alternative source of increased sCD163 in GDM, although this would have less impact in early 
pregnancy. The non-significant increase in sCD163 in another study of 66 GDM and 71 control 
women at 27 weeks of gestation 
32
 could partly be related to the relative late sampling. Furthermore, at 
14-16 weeks high sCD163 was associated with poorer β-cell function, but only in individuals with 
high BMI as also observed in T2DM 
29, 30
. As circulating sCD163 levels have been shown to correlate 
with CD163 expression, macrophage content and insulin sensitivity in adipose tissue 
33, 34
, we 
speculate that early activation of monocytes/macrophages and infiltration in adipose tissue may be an 
important event in the early development of GDM, at least in a subgroup of women with increased 
body mass. The association between sCD163 and insulin resistance at 30-32 weeks, as also observed 
in the above GDM studies 
31, 32
, may suggest a role for sCD163 and monocyte/macrophage activations 
in the normal adaption of insulin resistance in later pregnancy. Thus, our findings may reflect that 
macrophages exert distinct effects depending on the presence of adiposity, hyperglycemia and 
inflammation. In patients with T2DM and diabetic mice, increased sCD163 and a decreased 
percentage of CD163+ monocytes preceded the development of diabetic complications while shedding 
of sCD163 in response to inflammatory stimuli also may attenuate immune activation 
35, 36
. Our 
finding that sCD14, which also reflects monocyte activation, was not associated with GDM supports 
that the increased sCD163 in GDM to a larger degree reflects macrophage activation, although these 
markers may represent distinct but overlapping biological pathways or subtypes of macrophages.  
The discriminatory properties of markers at 14-16 weeks as early predictors of GDM were 
poor for most and modest for leptin, IL-1Ra and sCD163. However, multivariable regression including 
conventional risk factors, identified sCD163 as an independent predictor of GDM with a Wald-score 
similar to glucose, only surpassed by age. Further analysis of the diagnostic properties of sCD163 at 
14-16 weeks in predicting GDM using different cut-offs revealed that a specificity of 80% was 
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achieved at the 75
th
 percentile of sCD163 levels. At this level sensitivity was around 45%. Thus, 
evaluated as a stand-alone marker, sCD163 is not viable as an early screening biomarker to rule out 
women less likely to develop GDM. In combination with fasting glucose however (i.e. high glucose 
and high sCD163), we did find that more than half of the GDM cases could be identified when 25% of 
the population would score positive (i.e. high sCD163 and/or high glucose). As several studies have 
shown that calorie restriction reduces sCD163 in parallel to improvement in insulin resistance 
29, 33
, it 
would be interesting to monitor  sCD163 in existing dietary intervention studies in GDM.  
In contrast to several studies presenting elevated levels in chemerin between GDM and non-
GDM 
37
, also in early pregnancy 
38
, and presented in a recent meta-analysis
39
 we found similar levels 
in these groups. However, chemerin was correlated with BMI as well as insulin resistance/sensitivity 
in both early and late pregnancy, supporting a role for this protein in normal glucose homeostasis. In 
support of our lack of differences in several adipokines, a recent study evaluating a FABP4, leptin, 
chemerin, adiponectin  and resistin at 14 and 28 weeks of pregnancy in a high-risk GDM population 
(i.e. all with previous GDM) detected only lower levels of adiponectin 
40
. However, other studies have 
shown elevated levels of FABP4 in GDM
41, 42
 and in a systematic review they reported elevated levels 
of leptin in GDM and inconclusive result for resistin
26
 between GDM and non-GDM. Few studies 
have investigated circulating clusterin, sCD14 and adipsin in GDM women and our results could 
therefore not be compared to other studies. Discrepancies with previous studies could include timing 
of blood sample collection, different diagnostic criteria, population characteristics, sample size, and 
diverse assay method, to mention some. The strength of this study, however, includes the prospective 
design including four time-points in pregnancy and a well described cohort. 
Limitations to our study include a modest number of GDM women, without a history of 
diabetes mellitus or GDM limiting the interpretation of our results to concern normal pregnancies. 
Third, with regard to insulin resistance, central visceral fat as best evaluated by computed tomography, 
is strongly associated with insulin resistance and type 2 diabetes but not usable during pregnancy. 
Finally, the diagnosis of the GDM was performed later than the standard protocol, at 30-32 weeks and 
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not at 24-28 weeks as recommended, although the prevalence of GDM suggests that this is an average 
risk cohort when it comes to GDM risk. 
  In summary, we identified early alterations in adiponectin and sCD163 in GDM pregnancies. 
In early pregnancy, high sCD163 was associated with poor β-cell function but was associated with 
insulin resistance later in pregnancy. Our finding may suggest a complex role for 
sCD163+macrophages and indicate that early activation of monocytes/macrophages may be an 
important event in the early development of GDM, but could also have a role in the normal adaption 
of insulin resistance. Further evaluation of sCD163 as a risk marker and interactions between body 
mass, macrophage activation and β-cell function early in pregnancy of GDM women is warranted.   
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14-16 weeks 30-32 weeks  5 year FU 
N= 
Controls 225 225 225 
GDM 48 48 48 
Age (years) 
 
Controls 32 (4)  37 (4) 




Controls 169 (6)  169 (6) 
GDM 169 (6)  169 (6) 
Gestational weight 
gain (kg) V1-V4 
Controls 10.1 (8.0,12.6)   





Controls 23.4 (21.4, 25.5) 26.1 (23.8, 28.3) 22.6 (20.8, 24.5) 
GDM 26.0 (23.5, 28.5)** 28.4 (26.8, 29.8)** 24.8 (22.6, 27.9)* 
CRP (ng/mL) 
Controls 1.56 (0.88, 2.41) 1.37 (0.82, 2.16) 0.38 (0.19, 0.71) 
GDM 2.01 (1.18, 3.15)* 1.92 (1.03, 2.66)* 0.44 (0.25, 1.10) 
Primipara n (%) 
 
Controls 113 (50.9)  25 (11.1) 
GDM 19 (39.6)  5 (10.4) 
Currently smoking n 
(%) 
Controls 7 (3.8)  35 (19.8) 
GDM 1 (2.9)  12 (36.4)* 
Previous smoker 
n (%) 
Controls 39 (17.9)  48 (25.3) 
GDM 13 (27.7)  15 (41.7)* 
Family history 
diabetes n (%) 
Controls 69 (30.7)   
GDM 18 (37.5)   
Systolic blood 
pressure (mmHg) 
Controls 110 (100, 117)* 110 (105, 120) 110 (100, 120) 
GDM 110 (110, 120) 110 (105, 120) 110 (100, 130) 
Diastolic blood 
pressure (mmHg) 
Controls 65 (60, 70) 70 (60, 70) 70 (60, 74) 
GDM 70 (65, 70)* 70 (60, 75) 70 (65, 75) 
Matsuda-index 
 (insulin sensitivity) 
Controls 221 (158, 314) 124 (87, 183) 277 (209, 383) 
GDM 152 (102, 198)** 63 (45, 91)** 189 (138, 298)** 
ISSI-2  
(insulin resistance) 
Controls 0.71 (0.46, 1.04) 0.97 (0.67, 1.50) 0.64 (0.43, 0.94) 
GDM 1.0 (0.81, 1.67)** 2.01 (1.38, 2.73)** 1.04 (0.69, 1.31)** 
HOMA-IR  
(β-cell function) 
Controls 1195 (927, 1586) 1003 (781, 1282) 1050 (848, 1386) 
GDM 811 (615, 1078)** 549 (449, 653)** 760 (592, 1137)** 




) when skewed distributed.  p<0.05 *, 





Table 2. Levels of adipokines and macrophage markers at 5 years follow-up between previous GDM and non-
GDM 












IL1Ra (pg/mL) 45.1 (27.5, 72.2) 62.8 (41.8, 124.0) 7.6
b
 2.8 3.8 
Leptin (ng/mL) 24.5 (15.3, 40.7) 33.0 (24.9, 49.0) 9.1
b
 0.1 0.2 







Chemerin (ng/mL) 173 (150, 217) 191 (158, 221) 3.9
a
 0.6 0.4 
Clusterin (ng/mL) 457 (424, 486) 463 (432, 484) 0.1 0.1 0.1 
Resistin (ng/mL) 28.1 (21.3, 34.8) 28.8 (22.5, 35.0) 0.6 0.4 0.3 





sCD14 (µg/mL) 4.57 (4.23, 4.86) 4.63 (4.32, 4.84) 0.4 0.2 0.3 
In the three columns to the right, F-scores are shown. 
¶ 
Adjusted for BMI, 
$ 
adjusted for BMI, age, parity, 


















































Figure 2. Levels of adipokines and monocyte/macrophage markers in non-GDM and GDM during 
pregnancy.  A. The monocyte/macrophage activations markers sCD163 and IL-1Ra. B. The diabetic 
adipokines leptin and adiponectin and C. Other adipokines including chemerin, clusterin, resistin, 
adipsin and the monocyte/macrophage activation markers sCD14. Uni: univariate associations (i.e. 
unadjusted), BMI: adjusted for BMI, MULTI: multivariate associations (adjusted for BMI, age, parity, 


















Figure 3. Associations between adipokines, monocyte/macrophage markers and BMI, CRP, and 
glucose measures at 14-16 and 30-32 weeks. A. The monocyte/macrophage activations marker 
sCD163, showing the interaction between sCD163 and BMI with BMI dicotomized at 25. B. The 
monocyte/macrophage activations marker sCD14 and the diabetic adipokines leptin, adiponectin and 
chemerin C. the adipokines clusterin, resistin, adipsin and the monocyte/macrophage activation 
markers sCD14.  Univariate associations and multivariate associations adjusted for BMI are presented 
as regression coefficients and only significant associations are shown. In A, the interaction between 






Figure 4. Adipokines and monocyte/macrophage markers at 14-16 weeks as predictors of GDM at 30-
32 weeks. A. Receiver operating characteristic curves for predicting GDM by adipokines and 
macrophage markers at 14-16 weeks in pregnancy. Area with confidence intervals and p-values are 
shown to the right of the graph. B. Backward stepwise regression showing predictors (red circles) of 
GDM. BMI, age, family history of diabetes, parity and glucose were forced in the model in step 1 
while adipokines and monocyte/macrophage markers were included by backward regression in step 2. 
C. Test characteristics of different cut-offs of sCD163 at 14- 16 weeks in pregnancy based on 
percentiles obtained from the total population for predicting GDM. D. Sensitivity of fasting glucose 
and sCD163 alone or in combination at 14-16 weeks in predicting GDM. The green line shows the 
sensitivity obtained at the 75
th
 percentile, i.e. when 25% of the population is characterized as having a 
positive test.  
 
 
